within Pharmacolibrary.Drugs.ATC.H;

model H01AX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.57,
    Cl             = 36 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.0076,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Pegvisomant is a genetically engineered growth hormone receptor antagonist used in the treatment of acromegaly, a disorder caused by excessive secretion of growth hormone, usually due to pituitary adenoma. It is a pegylated protein administered via subcutaneous injection. Pegvisomant is approved for clinical use for acromegaly in numerous countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with acromegaly following subcutaneous administration; healthy volunteers and both sexes included in original studies.</p><h4>References</h4><ol><li><p>Jen, J, et al., &amp; Hey-Hadavi, JH (2013). Pegvisomant bioavailability of single 30 mg/mL subcutaneous injection compared to two 15 mg/mL subcutaneous injections: a pharmacokinetic, safety and tolerability study. <i>Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society</i> 23(4) 114–119. DOI:<a href=&quot;https://doi.org/10.1016/j.ghir.2013.04.002&quot;>10.1016/j.ghir.2013.04.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23651793/&quot;>https://pubmed.ncbi.nlm.nih.gov/23651793</a></p></li><li><p>Muto, C, et al., &amp; Suwa, T (2011). Population pharmacokinetic and pharmacodynamic modeling of pegvisomant in asian and Western acromegaly patients. <i>Journal of clinical pharmacology</i> 51(12) 1628–1643. DOI:<a href=&quot;https://doi.org/10.1177/0091270010386954&quot;>10.1177/0091270010386954</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21209237/&quot;>https://pubmed.ncbi.nlm.nih.gov/21209237</a></p></li><li><p>Yang, LP, &amp; Keating, GM (2010). Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. <i>Drugs</i> 70(13) 1745–1769. DOI:<a href=&quot;https://doi.org/10.2165/11204510-000000000-00000&quot;>10.2165/11204510-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20731479/&quot;>https://pubmed.ncbi.nlm.nih.gov/20731479</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end H01AX01;
